QCOM is inherently undervalued with strong growth prospects in numerous end markets, despite the potential geopolitical/ macroeconomic headwinds. Most importantly, we believe that the management is likely to achieve the aggressive non-handset revenue guidance of $22B in 2029, as observed in the growing design wins. These reasons are also why QCOM is likely to outperform the pessimistic consensus forward estimates, with it offering rich double-digits upside potential and dividend income growth.

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound

Currently, we have many signs pinpointing to a value factor outperforming growth. It seems that the dividend-oriented stocks might become the new glamour. In this article, I elaborate on the key reasons why I think so. I highlight 3 specific high and durable yield segments that could really deliver superior returns going.

Expected gross revenues at $2.0 billion TEN to become one of the largest independent Shuttle tanker operators

Set of seamlessly integrated tools to help employers drive cost savings, simplify spending decisions, and engage their employees Set of seamlessly integrated tools to help employers drive cost savings, simplify spending decisions, and engage their employees

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound® Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide. KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic ("PK") results from Human Study #3 or GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") …

ATLANTA , March 18, 2025 /PRNewswire/ -- Governor Brian P. Kemp today announced that TriNet is planning to create 750 new jobs at a new corporate center in Dunwoody, Georgia, over the next five years, representing an estimated $15.4 million in investment in DeKalb County.

NEW YORK--(BUSINESS WIRE)--DDC Enterprise, Ltd. (NYSEAM: DDC), (“DayDayCook,” “DDC,” or the “Company”), a leading multi-brand Asian consumer food company, today announced a transformative initiative to adopt Bitcoin as part of its treasury reserves, alongside an announcement that brings seasoned Web3 and Crypto Assets Management Expert Alex Yang to DDC as Strategic Advisor. An investor group will inject up to 100 BTC in exchange for DDC Class A Ordinary shares at a range of $0.50 to $1.25 per s.

Approval marks key milestone in the process to combine the two companies NEW YORK , March 18, 2025 /PRNewswire/ -- Omnicom (NYSE: OMC) and Interpublic (NYSE: IPG) today announced that each company's respective stockholders overwhelmingly approved Omnicom's previously announced acquisition of Interpublic at each company's Special Meeting of Stockholders held today. The companies remain on track to complete the transaction in the second half of 2025.

The real estate sector is off to a strong start in 2025, outperforming the S&P 500 (^GSPC 0.64%) by about 6 percentage points through mid-March. However, not all real estate investment trusts (REITs) have outperformed, and there are some excellent buying opportunities for patient long-term investors.

Block (XYZ) has gone by many names and ticker symbols. But, as the fintech company embraces its blockchain roots, the analyst community is weighing in as Keefe Bruyette upgraded the stock to an Outperform.

SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2025 / National plaintiffs law firm Lieff Cabraser Heimann & Bernstein, LLP encourages investors in Atkore Inc. ("Atkore" or the "Company") (NYSE:ATKR) who purchased Atkore common stock between August 2, 2022, and February 3, 2025, inclusive (the "Class Period") to contact us immediately regarding a pending securities class action against Atkore. The deadline to apply to be lead plaintiff is April 23, 2025.

LOS ANGELES , March 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Digimarc Corporation ("Digimarc" or "the Company") (NASDAQ: DMRC) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 2, 2024 and February 26, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before May 9, 2025.

GREENSBORO, N.C.--(BUSINESS WIRE)--UNIFI, Inc. (NYSE: UFI), the makers of REPREVE® and one of the world's leading innovators in recycled and synthetic yarns, is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025 in the Fashion and Apparel category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the e.

Getty Images Holdings, Inc. beat Q4 estimates with $247.3 million revenue and 6¢ EPS, showing signs of recovery despite past misses. The Shutterstock merger offers a strategic investment opportunity, potentially enhancing cash flow and reducing leverage for Getty Images. AI content growth is modest, with 2025 guidance suggesting revenue may decline due to the lack of major events.

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.

Access the CEO Connect segment here

Anthony Sassine examines Xpeng (XPEV) after the company's 4Q earnings report. The China EV maker says 4Q deliveries increased 52.1% Y/Y.

Meta's metaverse and Reality Labs have never really been appreciated by the market. I think this is a fundamental error. Augmented and virtual reality will almost certainly become a huge market with endless use cases from leisure, healthcare, gaming, military, to enterprise products. Meta is expected to have spent $100 billion in CapEx on virtual and augmented reality by year end 2025, with no competitor spending close to this amount.

Alphabet will buy cybersecurity startup Wiz for $32 billion, in a deal that represents the Google parent's biggest acquisition ever.